David Hung is recorded as CEO and Board Member at Nuvation Bio Inc. (NUVB), Board Member at NovoCure Ltd (NVCR) since January 1, 2018 and CEO at NovoCure Ltd (NVCR). The newest filing on record that lists David Hung as CEO and Board Member at Nuvation Bio Inc. (NUVB) is dated April 10, 2026. The newest filing on record that lists David Hung as CEO and Board Member at NovoCure Ltd (NVCR) is dated April 20, 2026. Earlier roles on record: Board Member at Establishment Labs Holdings Inc. (ESTA) until February 11, 2021. NovoCure Ltd reported in an 8-K filed June 5, 2026 that David Hung was appointed director, effective June 3, 2026. NovoCure Ltd reported in an 8-K filed June 6, 2025 that David Hung was appointed director, effective June 4, 2025. NovoCure Ltd reported in an 8-K filed June 10, 2024 that David Hung was appointed director, effective June 5, 2024. Equibles holds 4 filed executive changes naming David Hung; each is listed under recent activity with its source filing. The proxy statement of Nuvation Bio Inc. reports total compensation of $8,072,329 for David Hung in fiscal 2022, including a base salary of $570,004. Disclosed compensation is on record for 2 fiscal years. David Hung has spoken on 6 earnings calls and 6 other investor events across 1 company, most recently for Nuvation Bio Inc. on September 9, 2026. Nuvation Bio Inc. is classified in the Biotechnology industry within the Healthcare sector. NovoCure Ltd is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Nuvation Bio Inc. includes Moses Makunje (CFO and Chief Accounting Officer), Philippe Sauvage (CFO), Dr. Junyuan (Jerry) Wang (Board Member) and 7 others.
“The Company’s shareholders elected Asaf Danziger, William Doyle, Jeryl Hilleman, David Hung, Frank Leonard, Kinyip Gabriel Leung, Martin Madden, Allyson Ocean, Timothy Scannell, Kristin Stafford and William Vernon as directors, effective immediately, with a term expiring at the annual meeting of shareholders in 2027.”
“The Company's shareholders elected Ashley Cordova, Asaf Danziger, William Doyle, Jeryl Hilleman, David Hung, Kinyip Gabriel Leung, Martin Madden, Allyson Ocean, Timothy Scannell, Kristin Stafford and William Vernon as directors, effective immediately, with a term expiring at the annual meeting of shareholders in 2026.”
“As you know, Iptrosi got FDA approval a little over a year ago. We've had a little over a year of launch, and Iptrosi's been a very strong launch. We are already the number one ROS1 TKI today on the market.”
“I'm excited to discuss the continued progress we made across our business in the second quarter. Deptrosi delivered another strong quarter, with net revenue growing 25% to $23.2 million, in line with the median estimate from our 10 covering analysts.”
“Our two most advanced acids are Ibtrozi, an inhibitor of ROS1 for ROS1-positive non-small cell lung cancer. We started our commercial launch three-quarters ago.”
“So if you look at, we've been out for three quarters, and if you look at new patient starts in each quarter, it's been about 200 new patient starts per quarter, which is more than the combined new patient starts of Ogtiro and Intracnib combined.”
“So, for those who may be unfamiliar with Nuvation, give us a brief overview of the company and its pipeline. so we have three programs right now in trozi is a best-in-class Ross one inhibitor for a type of non small cell lung cancer that drug was approved in July last year we've had three quarters of launch which has…”
